Jan 13 (Reuters) - Abercrombie & Fitch (ANF.N), opens new tab on Monday raised its annual net sales growth target for the current ... it would buy drugmaker Intra-Cellular Therapies for about ...

BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...

I've been using the OnePlus 13 and OnePlus 13R for the past month—through the 2024 holiday season and CES 2025—which means ...

On Friday, BofA Securities analyst Jason Gerberry increased the price target on Intra-Cellular ... with Intra-Cellular Therapies' stock price rising by 13.5%, in contrast to the broader biotech ...

On Monday, Mizuho (NYSE:MFG) Securities updated its financial outlook for Intra-Cellular Therapies (NASDAQ:ITCI), increasing the stock's price target from ... following a 13% stock rise post ...

Intra-Cellular said last fall it was expanding its sales force to target growth opportunities with primary care doctors. The company also is seeking U.S. Food and Drug Administration approval to ...

It has made several transactions in the past few years to boost its pharmaceuticals and medical devices units, including a $13.1 billion deal ... each share of Intra-Cellular for $132 ...

Police are seeking information about a 13-year-old boy who ... increased 38%. Intra-Cellular said last fall it was expanding its sales force to target growth opportunities with primary care ...

Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn ...

The iPhone 13 is the Apple flagship from 2021 but it's still knocking around at a few select retailers. Not only is the chipsets inside and cameras decent, but the iPhone 13 share a design that is ...